Skip to main content
. 2019 Apr 11;116(18):9008–9013. doi: 10.1073/pnas.1821510116

Fig. 2.

Fig. 2.

Survival of patients with mesothelioma treated with platinum chemotherapy, by patient’s genotype and primary site of tumor. Survival of patients with an inherited damaging mutation in any targeted gene is indicated in blue; survival of patients with no inherited mutation is indicated in red. (A) All mesothelioma patients with versus without inherited mutations. Median survival: 8.0 vs. 2.9 y, P = 0.0006. (B) Pleural mesothelioma patients with versus without inherited mutations. Median survival: 7.9 vs. 2.4 y, P = 0.0012. (C) Peritoneal mesothelioma patients with versus without inherited mutation. Median survival: 8.2 vs. 5.4 y, P = 0.47.